We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

kindr currently serves patients in the United States only. Content is for informational purposes elsewhere.
Peptides shop · HIV-1 gag Protein p17 (76-84) · Reference sheet

HIV-1 gag Protein p17 (76-84)

Reference sheet · Viral Peptides · CPC catalog code HIV-014

Identity

Name
HIV-1 gag Protein p17 (76-84)
Catalog code
HIV-014
Category
Viral Peptides

Physicochemical properties

Sequence
H-Ser-Leu-Tyr-Asn-Thr-Val-Ala-Thr-Leu-OH (acetate salt)

Handling, storage & reconstitution

Upstream storage
CONDITIONS:**-20 ± 5 °C

General guidance for this class

Reference standards in the Viral Peptides class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.

Mechanism & research applications

HIV-1 gag Protein p17 (76-84) sits within the Viral Peptides research class (CPC reference HIV-014). Viral peptides map to functional regions of viral proteins — fusion peptides, receptor-binding domains, protease cleavage sites, and immunodominant epitopes — enabling targeted studies of entry, replication, and immune recognition. Investigators typically incorporate HIV-1 gag Protein p17 (76-84) as a reference standard, tool ligand, or substrate in the assay contexts listed above. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.

Studied for

  • Viral fusion and entry-inhibitor screening
  • Viral protease activity and inhibitor discovery
  • Antigenic-epitope mapping and vaccine research
  • Structure–activity relationship (SAR) on viral surface proteins

Frequently asked

What is HIV-1 gag Protein p17 (76-84)?

HIV-1 gag Protein p17 (76-84) (CPC catalog code HIV-014) is a synthetic viral / antiviral research peptide in the viral peptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

What is HIV-1 gag Protein p17 (76-84) studied for?

Published and internal research programs use HIV-1 gag Protein p17 (76-84) as a reference standard in viral peptides workflows — for example, viral fusion and entry-inhibitor screening and viral protease activity and inhibitor discovery. Human clinical evidence is not established.

Is HIV-1 gag Protein p17 (76-84) FDA-approved for human use?

No. HIV-1 gag Protein p17 (76-84) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

How is HIV-1 gag Protein p17 (76-84) typically used in the lab?

In a viral peptides workflow, HIV-1 gag Protein p17 (76-84) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.

Sources

View full product page →Back to catalog

Related peptides in Viral Peptides

Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.

HIV-1 gag Protein p24 (137-154)
HIV-1 gag Protein p24 (194-210)
HIV-1 tat Protein (1-9)
HIV-1 gag Protein p24 (65-73) (isolates MAL/U455)
HIV-1 gag Polyprotein (121-140)
HIV-1 rev Protein (34-50)
HIV-1 tat Protein (49-57)
HIV gag p24 (265-280)
Research use only. The peptides referenced on this page are supplied to qualified laboratories for in-vitro or non-human research. They are not drugs, foods, cosmetics, or dietary supplements, are not for human consumption, and are not intended to diagnose, treat, cure, or prevent any disease. Physicochemical values shown here are transcribed from the cited upstream reference sheet(s); confirm with your own certificate of analysis before use.
Ask Dot